Urolithin A counteracts cyclophosphamide-induced chemobrain in rats through modulation of mitochondrial signaling pathways

Key Points

• Urolithin A effectively counteracts the cognitive decline associated with cyclophosphamide treatment, improving brain function.
• Key evidence shows a notable improvement in cognitive tests observed after urolithin A administration in treated rats.
• Analysis focused on mitochondrial signaling pathways within the context of cyclophosphamide-induced damage, elucidating potential mechanisms.
• These findings suggest neuroprotection offered by urolithin A, indicating its significance in managing chemotherapy-related cognitive decline.